摘要
目的:观察探讨急性心肌梗死(AMI)经皮冠状动脉介入治疗(PCI)术后患者应用阿利西尤单抗、美托洛尔的效果及对心血管不良事件的预防作用。方法:回顾性选择2021年1月—2022年11月在佳木斯市中心医院心内科进行PCI术的85例AMI患者,根据术后不同治疗方式分为两组。对照组(n=43)PCI术后辅以美托洛尔治疗,联合组(n=42)PCI术后辅以阿利西尤单抗与美托洛尔联合治疗。评价两组心功能恢复效果,比较两组治疗前后C反应蛋白(CRP)、髓过氧化物酶(MPO)、脑钠肽(BNP)表达水平,观察两组心血管不良事件发生情况。结果:联合组心功能恢复优良率为90.48%,与对照组的69.77%比较,差异有统计学意义(P<0.05);治疗后两组CRP、MPO、BNP表达水平较治疗前均降低,且联合组治疗后均低于对照组,差异均有统计学意义(P<0.05)。联合组心血管不良事件总发生率低于对照组,差异有统计学意义(P<0.05)。结论:AMI患者PCI术后联合应用阿利西尤单抗、美托洛尔的临床疗效更佳,有利于心功能恢复,减少心血管不良事件,可能与CRP、MPO、BNP水平下调有关。
Objective:To observe and explore the effect of Alirocumab and Metoprolol in patients with acute myocardial infarction(AMI)after percutaneous coronary intervention(PCI)and its preventive effect on cardiovascular adverse events.Method:A total of 85 patients with AMI who underwent PCI in Department of CardiologyⅡ,Jiamusi Central Hospital from January 2021 to November 2022 were retrospectively selected and divided into two groups according to different postoperative treatment methods.The control group(n=43)was treated with Metoprolol after PCI,and the combined group(n=42)was treated with Alirocumab combined with Metoprolol after PCI.The recovery effect of cardiac function in two groups were evaluated.The expression levels of C reactive protein(CRP),myeloperoxidase(MPO)and brain natriuretic peptide(BNP)were compared between the two groups before and after treatment.The occurrence of cardiovascular adverse events in the two groups were observed.Result:The excellent and good rate of cardiac function recovery in the combined group was 90.48%,compared with 69.77%in the control group,the difference was statistically significant(P<0.05).The expression levels of CRP,MPO and BNP in both groups after treatment were lower than those before treatment,and those in the combined group were lower than those in the control group after treatment,the differences were statistically significant(P<0.05).The total incidence of cardiovascular adverse events in combined group was lower than that in control group,the difference was statistically significant(P<0.05).Conclusion:The clinical efficacy of Alirocumab combined with Metoprolol in patients with AMI after PCI is better,which is beneficial to the recovery of cardiac function and reduces cardiovascular adverse events,which may be related to the down-regulation of CRP,MPO and BNP levels.
作者
李志
雷锐
LI Zhi;LEI Rui(Department of CardiologyⅡ,Jiamusi Central Hospital,Jiamusi 154002,China;不详)
出处
《中国医学创新》
CAS
2024年第4期66-69,共4页
Medical Innovation of China
